Breaking News

Novozymes Re-brands Human Albumin Portfolio

January 23, 2013

Combines rAlbumin line under Recombumin name

Novozymes Biopharma has introduced a new brand for its recombinant human albumin (rAlbumin) portfolio, bringing both of its rAlbumin products under its established Recombumin brand. Albucult will be renamed Recombumin Alpha, and Recombumin will now be known as Recombumin Prime. The products, as well as the product codes, will remain the same, but there will be changes reflected on both marketing materials and product labeling.
 
“Novozymes is delighted to announce that it is synchronizing the branding of its rAlbumin products under the Recombumin family name to enhance the clarity of the company’s product offering, while still providing customers with the same superior solutions,” said Dermot Pearson, marketing director, Novozymes Biopharma. “Since we launched our rAlbumins the portfolio has gone from strength-to-strength helping Novozymes to become one of the fastest growing companies in the industry.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks